- An executive order was issued to accelerate research related to drug policy in the US.
- Executive order shifts cannabis classification from Schedule I to Schedule III.
- US cannabis rescheduling is expected to favor Tilray.
Tilray benefits from the easing of federal research restrictions on cannabis.
1 report, 1 independent
Updated Jul 19
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tilray benefits from the easing of federal research restrictions on cannabis.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Tilray
pharmaceutical and cannabis company
Related events
- Democrats winning seats could boost cannabis stocks, causing market surges when reform is discussed.
- Tilray secured a partnership to distribute medical cannabis products in Italy, while Trump's administration considers reclassifying cannabis.
- Tilray launched new medical cannabis strains in Germany, aiming to improve access in Europe's largest market.
- Aurora Cannabis and Tilray are driving market growth and leading innovations in European cannabis therapies.
Coverage
Newest first; wire copies grouped- StockStoryTilray (TLRY) Stock Trades Up, Here Is Why Shares of cannabis company Tilray Brands (NASDAQ:TLRY) jumped 3.3% in the afternoon session after President Trump signed a bill that could ease federal rese